JP2018527336A - ３−インドール置換誘導体、医薬組成物、および使用方法 - Google Patents
３−インドール置換誘導体、医薬組成物、および使用方法 Download PDFInfo
- Publication number
- JP2018527336A JP2018527336A JP2018506432A JP2018506432A JP2018527336A JP 2018527336 A JP2018527336 A JP 2018527336A JP 2018506432 A JP2018506432 A JP 2018506432A JP 2018506432 A JP2018506432 A JP 2018506432A JP 2018527336 A JP2018527336 A JP 2018527336A
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- indol
- phenyl
- sulfonyl
- benzenesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *c1c[n](*)c2cc(*)c(*)cc12 Chemical compound *c1c[n](*)c2cc(*)c(*)cc12 0.000 description 4
- ANYUHMHSOONIKF-UHFFFAOYSA-N CCCN(CCC=N)C(NCCNS(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O)=O Chemical compound CCCN(CCC=N)C(NCCNS(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O)=O ANYUHMHSOONIKF-UHFFFAOYSA-N 0.000 description 1
- RSZNQULXVIJVJA-UHFFFAOYSA-N CN(C(CN(C1)S(c(cc2)ccc2-c2c[nH]c3cc(F)ccc23)(=O)=O)=O)C1=O Chemical compound CN(C(CN(C1)S(c(cc2)ccc2-c2c[nH]c3cc(F)ccc23)(=O)=O)=O)C1=O RSZNQULXVIJVJA-UHFFFAOYSA-N 0.000 description 1
- UKYPNXUVLRQSOI-UHFFFAOYSA-N CN(C)C(CCNS(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O)=O Chemical compound CN(C)C(CCNS(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O)=O UKYPNXUVLRQSOI-UHFFFAOYSA-N 0.000 description 1
- AQGYUKXHLHYMHX-UHFFFAOYSA-N CNC(c(cc(cc1)-c2c[nH]c3cc(F)ccc23)c1S(N1CCNCC1)(=O)=O)=O Chemical compound CNC(c(cc(cc1)-c2c[nH]c3cc(F)ccc23)c1S(N1CCNCC1)(=O)=O)=O AQGYUKXHLHYMHX-UHFFFAOYSA-N 0.000 description 1
- KGYVMYHZZQRVHB-UHFFFAOYSA-N CS(c(c(CN)c1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O Chemical compound CS(c(c(CN)c1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O KGYVMYHZZQRVHB-UHFFFAOYSA-N 0.000 description 1
- VDXFXOOVWIKTGE-OKILXGFUSA-N C[C@H](C1)N[C@@H](C)CN1S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O Chemical compound C[C@H](C1)N[C@@H](C)CN1S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O VDXFXOOVWIKTGE-OKILXGFUSA-N 0.000 description 1
- HAVXYUYSVFFDAF-LLVKDONJSA-N C[C@H](CNS(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O)O Chemical compound C[C@H](CNS(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O)O HAVXYUYSVFFDAF-LLVKDONJSA-N 0.000 description 1
- OJOODCWBFOKGNX-UHFFFAOYSA-N Cc([nH]c1c2ccc(F)c1)c2-c(cc1)ccc1S(NCCc1ncc[nH]1)(=O)=O Chemical compound Cc([nH]c1c2ccc(F)c1)c2-c(cc1)ccc1S(NCCc1ncc[nH]1)(=O)=O OJOODCWBFOKGNX-UHFFFAOYSA-N 0.000 description 1
- JZRZPFQQIOFCGL-UHFFFAOYSA-N Cc1nnc(CNC/[O]=S/c(cc2)ccc2C(c(c(NC)c2)ccc2F)=C)[o]1 Chemical compound Cc1nnc(CNC/[O]=S/c(cc2)ccc2C(c(c(NC)c2)ccc2F)=C)[o]1 JZRZPFQQIOFCGL-UHFFFAOYSA-N 0.000 description 1
- LXIUPELUVIEOAP-UHFFFAOYSA-N NC([n]1c(cc(cc2)F)c2c(-c(cc2)ccc2S(N2CCNCC2)(=O)=O)c1)=O Chemical compound NC([n]1c(cc(cc2)F)c2c(-c(cc2)ccc2S(N2CCNCC2)(=O)=O)c1)=O LXIUPELUVIEOAP-UHFFFAOYSA-N 0.000 description 1
- MCUULSPCLNTZND-UHFFFAOYSA-N NCCN(CCN(C1)S(c(cc2)ccc2-c2c[nH]c3c2ccc(F)c3)(=O)=O)C1=O Chemical compound NCCN(CCN(C1)S(c(cc2)ccc2-c2c[nH]c3c2ccc(F)c3)(=O)=O)C1=O MCUULSPCLNTZND-UHFFFAOYSA-N 0.000 description 1
- QLGVTEJXKWYKRA-UHFFFAOYSA-N O=C1OC(CCNS(c(cc2)ccc2-c2c[nH]c3cc(F)ccc23)(=O)=O)=NN1 Chemical compound O=C1OC(CCNS(c(cc2)ccc2-c2c[nH]c3cc(F)ccc23)(=O)=O)=NN1 QLGVTEJXKWYKRA-UHFFFAOYSA-N 0.000 description 1
- VFQNXFRQJMGQJU-UHFFFAOYSA-N O=S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(N1CCOCC1)=O Chemical compound O=S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(N1CCOCC1)=O VFQNXFRQJMGQJU-UHFFFAOYSA-N 0.000 description 1
- CZKCKAFNBOJQNQ-CQSZACIVSA-N O=S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(N[C@H]1COCC1)=O Chemical compound O=S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(N[C@H]1COCC1)=O CZKCKAFNBOJQNQ-CQSZACIVSA-N 0.000 description 1
- ZBVVEAXIBGDORR-UHFFFAOYSA-N OC(CC1)NCCN1S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O Chemical compound OC(CC1)NCCN1S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O ZBVVEAXIBGDORR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562203032P | 2015-08-10 | 2015-08-10 | |
| US62/203,032 | 2015-08-10 | ||
| US201662309530P | 2016-03-17 | 2016-03-17 | |
| US62/309,530 | 2016-03-17 | ||
| PCT/IB2016/054701 WO2017025868A1 (en) | 2015-08-10 | 2016-08-04 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018527336A true JP2018527336A (ja) | 2018-09-20 |
| JP2018527336A5 JP2018527336A5 (enExample) | 2019-09-05 |
Family
ID=56801656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506432A Ceased JP2018527336A (ja) | 2015-08-10 | 2016-08-04 | ３−インドール置換誘導体、医薬組成物、および使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10544095B2 (enExample) |
| EP (1) | EP3334733A1 (enExample) |
| JP (1) | JP2018527336A (enExample) |
| CA (1) | CA2994917A1 (enExample) |
| WO (1) | WO2017025868A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017019699A2 (pt) * | 2015-03-17 | 2018-09-04 | Pfizer Inc. | derivados substituídos por 3-indol, composições farmacêuticas e métodos para uso |
| EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| CN109414596B (zh) * | 2016-05-12 | 2023-09-29 | 密歇根大学董事会 | Ash1l抑制剂和用其进行治疗的方法 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3269714A1 (en) * | 2016-07-13 | 2018-01-17 | Netherlands Translational Research Center B.V. | Inhibitors of tryptophan 2,3-dioxygenase |
| GB201705263D0 (en) | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| SG10202107880XA (en) | 2017-05-12 | 2021-09-29 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
| CN108948002A (zh) * | 2017-05-19 | 2018-12-07 | 厦门大学 | 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用 |
| JP2020522495A (ja) | 2017-05-30 | 2020-07-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CA3078969A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
| US10632209B2 (en) | 2017-11-10 | 2020-04-28 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| CN108794376B (zh) * | 2018-04-28 | 2021-01-05 | 北京施安泰医药技术开发有限公司 | 甲酰胺类衍生物、其药物组合物、制备方法与用途 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN119306844A (zh) | 2018-09-25 | 2025-01-14 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| WO2021174058A1 (en) * | 2020-02-27 | 2021-09-02 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of apc-deficient cancer |
| CN111825678A (zh) * | 2020-06-05 | 2020-10-27 | 连庆泉 | 一种卡马替尼的制备方法 |
| CN116234568A (zh) | 2020-07-07 | 2023-06-06 | 生物技术公司 | 用于hpv阳性癌症的治疗性rna |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| CN119156403A (zh) | 2022-03-08 | 2024-12-17 | 阿伦蒂斯治疗股份公司 | 抗紧密连接蛋白-1抗体增加t细胞可用性的用途 |
| JP2026501506A (ja) | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| AR134560A1 (es) | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010534665A (ja) * | 2007-07-25 | 2010-11-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルココルチコイドミメチックス、それらの製造方法、医薬組成物、及びこれらの使用 |
| WO2015082499A2 (en) * | 2013-12-03 | 2015-06-11 | Iomet Pharma Ltd | Pharmaceutical compound |
| WO2018011227A1 (en) * | 2016-07-13 | 2018-01-18 | Netherlands Translational Research Center B.V. | Inhibitors of tryptophan 2,3-dioxygenase |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509731C2 (sv) | 1996-05-14 | 1999-03-01 | Labwell Ab | Metod för palladium-katalyserade organiska reaktioner innefattande ett uppvärmningssteg utfört med mikrovågsenergi |
| JP2000095759A (ja) | 1998-07-21 | 2000-04-04 | Takeda Chem Ind Ltd | 三環性化合物、その製造法および剤 |
| US6265403B1 (en) | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
| US20030109550A1 (en) | 2001-09-19 | 2003-06-12 | Michael Clare | Substituted indazole compounds for the treatment of inflammation |
| EP1490365B1 (en) | 2002-03-28 | 2010-02-10 | Eisai R&D Management Co., Ltd. | Azaindoles as inhibitors of c-jun n-terminal kinases |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| FR2845996A1 (fr) | 2002-10-16 | 2004-04-23 | Servier Lab | Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN1795187A (zh) | 2003-03-27 | 2006-06-28 | 兰肯瑙医学研究所 | 新型ido抑制剂及其使用方法 |
| FR2862647B1 (fr) | 2003-11-25 | 2008-07-04 | Aventis Pharma Sa | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
| GB0328909D0 (en) | 2003-12-12 | 2004-01-14 | Syngenta Participations Ag | Chemical compounds |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| RS51826B (sr) | 2005-02-09 | 2012-02-29 | Arqule Inc. | Maleimid derivati, farmaceutske kompozicije i postupak lečenja kancera |
| WO2007039580A1 (en) | 2005-10-05 | 2007-04-12 | Nycomed Gmbh | Imidazolyl-substituted benzophenone compounds |
| WO2007045622A1 (en) | 2005-10-18 | 2007-04-26 | Nycomed Gmbh | Oxazolo [4 , 5-b] pyridine compounds as nitric oxide synthase inhibitors |
| EP1940787A4 (en) | 2005-10-27 | 2009-07-01 | Lankenau Inst Medical Res | NEW IDO HEMMER AND APPLICATION METHOD THEREFOR |
| NZ568910A (en) | 2006-01-24 | 2011-04-29 | Lilly Co Eli | Indole sulfonamide modulators of progesterone receptors |
| US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| CA2645633A1 (en) | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| GB0624308D0 (en) | 2006-12-05 | 2007-01-17 | Molmed Spa | Combination product |
| BRPI0720049A2 (pt) | 2006-12-07 | 2014-01-07 | Novartis Ag | Derivados de piridina utilizados como inibidores de xiap |
| EP2121613A2 (en) | 2007-01-31 | 2009-11-25 | Vertex Pharmaceuticals, Inc. | 2-aminopyridine derivatives useful as kinase inhibitors |
| EP2137168B1 (en) | 2007-03-16 | 2016-09-14 | Lankenau Institute for Medical Research | Novel ido inhibitors and methods of use thereof |
| US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| WO2009073497A2 (en) | 2007-11-30 | 2009-06-11 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| ES2524259T3 (es) * | 2008-03-24 | 2014-12-04 | Novartis Ag | Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida |
| WO2010008427A1 (en) | 2008-04-11 | 2010-01-21 | Ludwig Institute For Cancer Research Ltd. | Tryptophan catabolism in cancer treatment and diagnosis |
| DE102008052943A1 (de) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
| CA2752596A1 (en) | 2009-02-17 | 2010-08-26 | Vertex Pharmaceuticals Incorporated | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase |
| SG182247A1 (en) | 2009-05-27 | 2012-08-30 | Hoffmann La Roche | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| CA2668905A1 (en) * | 2009-06-15 | 2010-12-15 | University Of Saskatchewan | Method for inhibiting brassinin oxidase |
| KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| AU2010298168B2 (en) | 2009-09-23 | 2015-11-19 | Medivation Technologies, Inc. | Pyrido(3,4-b)indoles and methods of use |
| CN102573478B (zh) | 2009-10-12 | 2015-12-16 | 拜尔农作物科学股份公司 | 作为杀虫剂的1-(吡啶-3-基)-吡唑和1-(嘧啶-5-基)-吡唑 |
| ES2749504T3 (es) | 2009-10-13 | 2020-03-20 | Ligand Pharm Inc | Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos |
| WO2012068406A2 (en) | 2010-11-18 | 2012-05-24 | Ligand Pharmaceuticals Incorporated | Use of hematopoietic growth factor mimetics |
| WO2012129338A1 (en) | 2011-03-22 | 2012-09-27 | Amgen Inc. | Azole compounds as pim inhibitors |
| LT2714677T (lt) | 2011-05-23 | 2018-12-10 | Merck Patent Gmbh | Piridino ir pirazino dariniai |
| AU2012296529A1 (en) | 2011-08-17 | 2014-02-20 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| US20160263087A1 (en) | 2013-11-08 | 2016-09-15 | Iteos Therapeutics | Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| US9126984B2 (en) | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| US9758505B2 (en) | 2014-02-12 | 2017-09-12 | Iteos Therapeutics | 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use |
| WO2015140717A1 (en) | 2014-03-18 | 2015-09-24 | Iteos Therapeutics | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| US20150266857A1 (en) | 2014-03-18 | 2015-09-24 | Iteos Therapeutics | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| EA201650031A1 (ru) | 2014-05-15 | 2017-06-30 | Итеос Терапьютик | Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1 |
-
2016
- 2016-08-04 US US15/749,963 patent/US10544095B2/en active Active
- 2016-08-04 WO PCT/IB2016/054701 patent/WO2017025868A1/en not_active Ceased
- 2016-08-04 JP JP2018506432A patent/JP2018527336A/ja not_active Ceased
- 2016-08-04 EP EP16757354.2A patent/EP3334733A1/en not_active Withdrawn
- 2016-08-04 CA CA2994917A patent/CA2994917A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010534665A (ja) * | 2007-07-25 | 2010-11-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルココルチコイドミメチックス、それらの製造方法、医薬組成物、及びこれらの使用 |
| WO2015082499A2 (en) * | 2013-12-03 | 2015-06-11 | Iomet Pharma Ltd | Pharmaceutical compound |
| WO2018011227A1 (en) * | 2016-07-13 | 2018-01-18 | Netherlands Translational Research Center B.V. | Inhibitors of tryptophan 2,3-dioxygenase |
Non-Patent Citations (1)
| Title |
|---|
| DATABASE REGISTRY, JPN7020001518, 16 December 2011 (2011-12-16), ISSN: 0004281223 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017025868A1 (en) | 2017-02-16 |
| EP3334733A1 (en) | 2018-06-20 |
| US20180222862A1 (en) | 2018-08-09 |
| US10544095B2 (en) | 2020-01-28 |
| CA2994917A1 (en) | 2017-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10544095B2 (en) | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | |
| JP6775516B2 (ja) | 新奇な３−インドール置換誘導体、医薬組成物、および使用方法 | |
| CN111377917B (zh) | 杂环类化合物、中间体、其制备方法及应用 | |
| CN1700918B (zh) | 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂 | |
| JP6104268B2 (ja) | パーキンソン病の処置のためのキナーゼｌｒｒｋ２モジュレーターとしての２−フェニルアミノピリミジン誘導体 | |
| RU2587493C2 (ru) | Производные диаминопиримидина и способы их получения | |
| CN115397821A (zh) | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 | |
| CN103459369B (zh) | 胍化合物 | |
| JP5713367B2 (ja) | Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体 | |
| CN112638373A (zh) | 细胞周期蛋白依赖性激酶抑制剂 | |
| US20160263087A1 (en) | Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use | |
| TWI647227B (zh) | ２－醯胺噻唑衍生物或其鹽 | |
| US20150328228A1 (en) | Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use | |
| JP2017507983A (ja) | 新規な３−インドール置換誘導体、医薬組成物、および使用方法 | |
| JP2017505346A (ja) | 新規な３−（インドール−３−イル）−ピリジン誘導体、医薬組成物、および使用方法 | |
| CN107592861A (zh) | 氟化赖氨酰氧化酶样2抑制剂及其用途 | |
| CN105189480A (zh) | 在治疗由IKKε和/或TBK-1机制介导的疾病中有用的嘧啶化合物 | |
| EP1730114A1 (en) | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | |
| JP2009541268A (ja) | Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体 | |
| PT1802307E (pt) | Derivados de pirrolidina como ligandos de receptores de histamina | |
| JP2016535097A (ja) | ４−（インドール−３−イル）−ピラゾール誘導体、医薬組成物および使用のための方法 | |
| HK1207855A1 (en) | Substituted carbamate compounds and their use as transient receptor potential (trp) channel antagonists | |
| HK1100823A1 (en) | 3-or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands | |
| HK1100823B (en) | 3-or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190723 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190723 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200528 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200630 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200909 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210323 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20210817 |